Shares of Q32 Bio Inc. (NASDAQ:QTTB) rose 60% on Monday after the company reported positive topline findings at 36 weeks from Part B of its SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with severe or very severe alopecia areata.
The trial achieved its primary endpoint. In the prespecified modified intent-to-treat (mITT) analysis, patients experienced a mean percent reduction in SALT score from baseline of 35.3%. In addition, 40.0% of patients reached a SALT-20 response at Week 36 in the mITT analysis, while the intent-to-treat (ITT) analysis of all enrolled patients showed a 30.3% SALT-20 response rate.
Part B enrolled 33 patients who had baseline SALT scores between 50 and 100, reflecting severe to very severe disease. Of those enrolled, 36.4% had a history of prior treatment with oral JAK inhibitors. The dosing regimen began with a loading phase of 200 mg of bempikibart administered weekly for four doses, followed by maintenance dosing of 200 mg every other week for the subsequent 32-week period.
On safety, bempikibart was described as generally well tolerated. There were no serious adverse events or Grade 3 or higher adverse events considered related to treatment. The most frequent treatment-emergent adverse event was injection site reaction, occurring in 36.3% of patients; these reactions were primarily mild and resolved without intervention.
Q32 Bio said the topline results support further development of bempikibart in alopecia areata and that the company intends to move forward with a registration-directed program in the first half of 2027. The company also indicated it will present full Part B results at a future medical meeting.
Bempikibart is described as a fully human anti-IL-7Rα antibody designed to re-regulate adaptive immune function by blocking IL-7 and TSLP signaling.
Clear summary - In this Phase 2a Part B readout, Q32 Bio reported a 35.3% mean reduction in SALT score in the prespecified mITT analysis, with SALT-20 responder rates of 40.0% (mITT) and 30.3% (ITT). The 33-patient cohort included prior oral JAK inhibitor exposure in 36.4% of participants. Safety findings were favorable, led by mostly mild injection site reactions at 36.3%. The company plans a registration-directed program in the first half of 2027 and will release full results at a future medical meeting.
Key points
- Clinical efficacy - The SIGNAL-AA Part B trial met its primary endpoint with a 35.3% mean reduction in SALT score in the prespecified mITT cohort at Week 36 and showed SALT-20 responder rates of 40.0% (mITT) and 30.3% (ITT).
- Patient population and dosing - The study enrolled 33 patients with baseline SALT scores of 50-100; 36.4% had prior oral JAK inhibitor treatment. The regimen used a 200 mg weekly loading for four doses, then 200 mg every other week for 32 weeks.
- Safety profile - No treatment-related serious adverse events or Grade 3+ events were reported. Injection site reactions were the most common treatment-emergent adverse event at 36.3%, generally mild and self-resolving.
- Market and sector impact - The results affected equity markets and are particularly relevant to the biotech and clinical development sectors, as well as healthcare investors tracking immunology and dermatology therapeutics.
Risks and uncertainties
- Sample size limitation - The Part B topline results derive from 33 enrolled patients, which is a small cohort and may limit the breadth of conclusions that can be drawn from these data.
- Topline data only - The company has released topline results and stated it will present full Part B data at a future medical meeting, indicating that detailed efficacy and safety analyses are still pending.
- Development timeline uncertainty - While Q32 Bio intends to pursue a registration-directed program in the first half of 2027, this timeline reflects the company’s plan rather than a guaranteed outcome.
The company’s announcement and the topline readout prompted the pronounced stock move, and Q32 Bio has flagged plans to provide more comprehensive trial data at an upcoming medical forum.